The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
UTD2 is the world's first oral epothilone microtubule inhibitor
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
